In CMV-specific CD8+ T cells, other upstream regulators are predicted to be less active in CLL, especially IL-13, transglutamase-2 (TGM2) and IFNγ (Fig. 4E). This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.